Abstract
Purpose
Preclinical activity of irinotecan has been seen in glioma models, but only modest efficacy has been noted in clinical studies, perhaps related to drug distribution and/or pharmacokinetic limitations. In preclinical testing, irinotecan liposome injection (nal-IRI) results in prolongation of drug exposure and higher tissue levels of drug due to slower metabolism and the effect of enhanced permeability and retention. The objective of the current study was to assess the safety and pharmacokinetics (PK) of nal-IRI and to determine the maximum tolerated dose (MTD) in patients with recurrent high-grade glioma stratified based on UGT1A1 genotyping.
Methods
This phase I study stratified patients with recurrent high-grade glioma into 2 groups by UGT1A1 status: homozygous WT (“WT”) vs heterozygous WT/*28 (“HT”). Patients who were homozygous *28 were ineligible. The design was a standard 3 + 3 phase I design. WT patients were started at 120 mg/m2 intravenously every 3 weeks with dose increases in 60 mg/m2 increments. HT patients were started at 60 mg/m2, with dose increases in 30 mg/m2 increments. The assessment period for dose-limiting toxicity was 1 cycle (21 days).
Results
In the WT cohort (n = 16), the MTD was 120 mg/m2. In the HT cohort (n = 18), the MTD was 150 mg/m2. Dose-limiting toxicity in both cohorts included diarrhea, some with associated dehydration and/or fatigue. PK results were comparable to those seen in other PK studies of nal-IRI; UGT1A1*28 genotype (WT vs. HT) did not affect PK parameters.
Conclusions
Nal-IRI had no unexpected toxicities when given intravenously. Of note, UGT1A1 genotype did not correlate with toxicity or affect PK profile.
References
Ostrom QT, Gittleman H, Fulop J, Liu M, Blanda R, Kromer C et al (2015) CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2008–2012. Neurooncology 17(Suppl 4):iv1–iv62
Drummond DC, Noble CO, Guo Z, Hong K, Park JW, Kirpotin DB (2006) Development of a highly active nanoliposomal irinotecan using a novel intraliposomal stabilization strategy. Cancer Res 66(6):3271–3277
Kalra AV, Kim J, Klinz SG, Paz N, Cain J, Drummond DC et al (2014) Preclinical activity of nanoliposomal irinotecan is governed by tumor deposition and intratumor prodrug conversion. Cancer Res 74(23):7003–7013
Kang MH, Wang J, Makena MR, Lee JS, Paz N, Hall CP et al (2015) Activity of MM-398, nanoliposomal irinotecan (nal-IRI), in Ewing’s family tumor xenografts is associated with high exposure of tumor to drug and high SLFN11 expression. Clin Cancer Res Off J Am Assoc Cancer Res 21(5):1139–1150
Noble CO, Krauze MT, Drummond DC, Forsayeth J, Hayes ME, Beyer J et al (2014) Pharmacokinetics, tumor accumulation and antitumor activity of nanoliposomal irinotecan following systemic treatment of intracranial tumors. Nanomedicine (London, England) 9(14):2099–2108
Chen PY, Ozawa T, Drummond DC, Kalra A, Fitzgerald JB, Kirpotin DB et al (2013) Comparing routes of delivery for nanoliposomal irinotecan shows superior anti-tumor activity of local administration in treating intracranial glioblastoma xenografts. Neurooncology 15(2):189–197
Chang TC, Shiah HS, Yang CH, Yeh KH, Cheng AL, Shen BN et al (2015) Phase I study of nanoliposomal irinotecan (PEP02) in advanced solid tumor patients. Cancer Chemother Pharmacol 75(3):579–586
Roy AC, Park SR, Cunningham D, Kang YK, Chao Y, Chen LT et al (2013) A randomized phase II study of PEP02 (MM-398), irinotecan or docetaxel as a second-line therapy in patients with locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma. Ann Oncol Off J Eur Soc Med Oncol ESMO 24(6):1567–1573
Ramanathan RK, Korn RL, Sachdev JC, Fetterly GJ, Jameson G, Marceau K et al (2014) Lesion characterization with ferumoxytol MRI in patients with advanced solid tumors and correlation with treatment response to MM-398, nanoliposomal irinotecan (nal-IRI). Eur J Cancer 50(Suppl 6):87 (abstract 261)
Wang-Gillam A, Li CP, Bodoky G, Dean A, Shan YS, Jameson G et al (2016) Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial. Lancet (London, England) 387(10018):545–557
Ando Y, Saka H, Ando M, Sawa T, Muro K, Ueoka H et al (2000) Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. Cancer Res 60(24):6921–6926
Innocenti F, Undevia SD, Iyer L, Chen PX, Das S, Kocherginsky M et al (2004) Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol Off J Am Soc Clin Oncol 22(8):1382–1388
Iyer L, Das S, Janisch L, Wen M, Ramirez J, Karrison T et al (2002) UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity. Pharmacogenomics J 2(1):43–47
Stewart CF, Panetta JC, O’Shaughnessy MA, Throm SL, Fraga CH, Owens T et al (2007) UGT1A1 promoter genotype correlates with SN-38 pharmacokinetics, but not severe toxicity in patients receiving low-dose irinotecan. J Clin Oncol Off J Am Soc Clin Oncol 25(18):2594–2600
Hoskins JM, Goldberg RM, Qu P, Ibrahim JG, McLeod HL (2007) UGT1A1*28 genotype and irinotecan-induced neutropenia: dose matters. J Natl Cancer Inst 99(17):1290–1295
Noble CO, Krauze MT, Drummond DC, Yamashita Y, Saito R, Berger MS et al (2006) Novel nanoliposomal CPT-11 infused by convection-enhanced delivery in intracranial tumors: pharmacology and efficacy. Cancer Res 66(5):2801–2806
Krauze MT, Noble CO, Kawaguchi T, Drummond D, Kirpotin DB, Yamashita Y et al (2007) Convection-enhanced delivery of nanoliposomal CPT-11 (irinotecan) and PEGylated liposomal doxorubicin (Doxil) in rodent intracranial brain tumor xenografts. Neurooncology 9(4):393–403
Dickinson PJ, LeCouteur RA, Higgins RJ, Bringas JR, Roberts B, Larson RF et al (2008) Canine model of convection-enhanced delivery of liposomes containing CPT-11 monitored with real-time magnetic resonance imaging: laboratory investigation. J Neurosurg 108(5):989–998
Acknowledgements
The authors would like to thank Ms. Ilona Garner (UCSF) for her expert assistance with manuscript preparation and editing.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Funding
This clinical trial was funded by the UCSF Brain Tumor Research Center’s Specialized Program of Research Excellence (SPORE) Grant from the NCI: P50 CA097257.
Conflict of interest
Daryl C. Drummond is both an employee and stockholder in Merrimack, and is the inventor of Onivyde (liposomal irinotecan). Jonathan B. Fitzgerald is an employee of Merrimack. Charles Noble is a stockholder in Merrimack.
Rights and permissions
About this article
Cite this article
Clarke, J.L., Molinaro, A.M., Cabrera, J.R. et al. A phase 1 trial of intravenous liposomal irinotecan in patients with recurrent high-grade glioma. Cancer Chemother Pharmacol 79, 603–610 (2017). https://doi.org/10.1007/s00280-017-3247-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00280-017-3247-3